Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.
作者信息
Bastian Mike, Freemantle Nick, Rossi Ana B, Shumel Brad, Le Bagousse Gaelle Bego, Wang Zhixiao, Xu Yingxin, Guyot Patricia
机构信息
Sanofi, Frankfurt, Germany.
Institute for Clinical Trials and Methodology, UCL, London, UK.
出版信息
Dermatol Ther (Heidelb). 2024 Mar;14(3):819-821. doi: 10.1007/s13555-024-01106-2. Epub 2024 Feb 16.
Abstract
摘要
相似文献
1
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.致编辑的信：关于“中度至重度特应性皮炎中乐必妥单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较”
Dermatol Ther (Heidelb). 2024 Mar;14(3):819-821. doi: 10.1007/s13555-024-01106-2. Epub 2024 Feb 16.
2
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".对《致编辑的信：关于“中度至重度特应性皮炎中乐布利单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较”》的回复
Dermatol Ther (Heidelb). 2024 Mar;14(3):823-827. doi: 10.1007/s13555-024-01107-1. Epub 2024 Mar 5.
3
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.中度至重度特应性皮炎中，乐必妥珠单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较
Dermatol Ther (Heidelb). 2024 Jan;14(1):169-182. doi: 10.1007/s13555-023-01058-z. Epub 2023 Oct 28.
4
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.对《中度至重度特应性皮炎中乐布利珠单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较》的更正
Dermatol Ther (Heidelb). 2024 Jan;14(1):183-185. doi: 10.1007/s13555-023-01076-x.
5
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.来布立izumab治疗中度至重度特应性皮炎青少年患者的安全性和有效性：一项为期52周的开放标签3期研究。
Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date.使用乌帕替尼治疗特应性皮炎——迄今的证据
Clin Cosmet Investig Dermatol. 2022 Jun 8;15:1065-1072. doi: 10.2147/CCID.S295672. eCollection 2022.
8
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
9
The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.Lebrikizumab 在成年特应性皮炎治疗中的作用。
Immunotherapy. 2023 Sep;15(13):981-991. doi: 10.2217/imt-2023-0066. Epub 2023 Jul 4.
10
Dupilumab in the treatment of moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎
Expert Rev Clin Immunol. 2017 Apr;13(4):301-310. doi: 10.1080/1744666X.2017.1292134. Epub 2017 Feb 15.
引用本文的文献
1
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.使用安慰剂调整后的间接治疗比较，度普利尤单抗与乐布利尤单抗相比，在疗效结果上实现并维持改善的可能性更大。
Dermatol Ther (Heidelb). 2025 Jul 11. doi: 10.1007/s13555-025-01479-y.
本文引用的文献
1
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.中度至重度特应性皮炎中，乐必妥珠单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较
Dermatol Ther (Heidelb). 2024 Jan;14(1):169-182. doi: 10.1007/s13555-023-01058-z. Epub 2023 Oct 28.
2
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Lebrikizumab 在中重度特应性皮炎中的疗效和安全性：两项随机双盲安慰剂对照 III 期临床试验的 52 周结果。
Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022.
3
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.多种度普利尤单抗剂量方案在特应性皮炎初始成功治疗后的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617.
4
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.健康保健决策中的间接治疗比较和网络荟萃分析解读：ISPOR 间接治疗比较良好实践工作组报告：第 1 部分。
Value Health. 2011 Jun;14(4):417-28. doi: 10.1016/j.jval.2011.04.002.
5
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.随机对照试验荟萃分析中直接和间接治疗比较的结果。
J Clin Epidemiol. 1997 Jun;50(6):683-91. doi: 10.1016/s0895-4356(97)00049-8.
Zotero 插件